Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN M SPERGEL

Allopathic & Osteopathic Physicians Pediatrics Pediatric Allergy/Immunology

NPI
1043226996
CMS profile
137580
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$107,403.65

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $79,773.44 61
Regeneron Pharmaceuticals, Inc. $10,241.59 6
E.R. Squibb & Sons, L.L.C. $5,616.00 2
Regeneron Healthcare Solutions, Inc. $4,744.00 3
NOVARTIS PHARMACEUTICALS CORPORATION $4,466.98 4
kaleo, Inc. $2,561.64 2

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN M SPERGEL

NPI 1043226996 · CMS profile ID 137580

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Allergy/Immunology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043226996?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN M SPERGEL, NPI 1043226996, CMS profile ID 137580. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043226996?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JONATHAN M SPERGEL, NPI 1043226996, CMS profile ID 137580. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043226996?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JONATHAN M SPERGEL, NPI 1043226996, CMS profile ID 137580, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1043226996?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $107,403.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $62.6804/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778557 CMS
GENZYME CORPORATION $169.8604/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778563 CMS
GENZYME CORPORATION $102.0704/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778569 CMS
GENZYME CORPORATION $42.6404/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778447 CMS
GENZYME CORPORATION $30.9904/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778455 CMS
GENZYME CORPORATION $559.6904/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778459 CMS
GENZYME CORPORATION $22.9104/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778467 CMS
GENZYME CORPORATION $650.0004/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778489 CMS
GENZYME CORPORATION $7,200.0003/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778483 CMS
GENZYME CORPORATION $559.6902/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061213415 CMS
GENZYME CORPORATION $22.9102/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061213417 CMS
GENZYME CORPORATION $30.9902/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061213419 CMS
GENZYME CORPORATION $7,200.0002/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061213421 CMS
GENZYME CORPORATION $42.6402/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061213425 CMS
kaleo, Inc. $61.6402/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013039595 CMS
GENZYME CORPORATION $117.0502/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778471 CMS
GENZYME CORPORATION $3,113.0002/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778479 CMS
GENZYME CORPORATION $6,227.0001/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778377 CMS
GENZYME CORPORATION $311.8401/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778383 CMS
GENZYME CORPORATION $579.7801/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778387 CMS
GENZYME CORPORATION $39.0301/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778393 CMS
GENZYME CORPORATION $155.3501/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778399 CMS
GENZYME CORPORATION $122.0401/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778405 CMS
GENZYME CORPORATION $2,669.0001/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778411 CMS
GENZYME CORPORATION $263.3301/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778417 CMS
GENZYME CORPORATION $579.7701/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778423 CMS
GENZYME CORPORATION $33.4901/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778429 CMS
GENZYME CORPORATION $155.3501/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049778439 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12,435.01 12
PY2020 $43,852.79 26
PY2021 $38,315.15 16
PY2022 $55,117.77 30
PY2023 $107,403.65 78
PY2024 $47,378.08 64
PY2025 $73,176.86 31

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,181.44 11
PY2025 Principal investigator $326,413.13 48
PY2024 Recipient $33,103.14 42
PY2024 Principal investigator $211,864.48 23
PY2023 Recipient $14,045.23 30
PY2023 Principal investigator $112,763.47 11
PY2022 Recipient $13,021.06 23
PY2022 Principal investigator $259,973.98 59
PY2021 Recipient $8,272.76 13
PY2021 Principal investigator $517,428.24 50
PY2020 Recipient $3,645.77 10
PY2020 Principal investigator $507,493.15 62
PY2019 Recipient $915.15 5
PY2019 Principal investigator $266,059.80 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,552.40 12/16/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83,459.71 12/16/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137497
Principal investigator 1 SANOFI US SERVICES INC. $5,206.50 12/08/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226129750
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $1,000.00 11/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,142.95 11/18/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137489
Principal investigator 1 SANOFI US SERVICES INC. $1,675.00 11/04/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226129747
Recipient Regeneron Pharmaceuticals, Inc. $101.54 11/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122970
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $1,000.00 10/31/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,273.95 10/28/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137487
Principal investigator 1 SANOFI US SERVICES INC. $3,951.00 10/14/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226129739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,390.98 10/01/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,639.96 10/01/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,861.75 10/01/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137483
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $765.00 09/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870921
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $5,609.28 09/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870925
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $612.00 09/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870929
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $9,875.44 09/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870935
Principal investigator 1 SANOFI US SERVICES INC. $2,048.40 09/22/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226129729
Recipient GENZYME CORPORATION $1,250.00 09/08/2025 Covered Recipient Physician A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE) No dispute reported 06/30/2026 1226097082
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $1,599.40 08/31/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870912
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $765.00 08/31/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870917
Principal investigator 1 SANOFI US SERVICES INC. $2,048.40 08/25/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226129722
Principal investigator 1 SANOFI US SERVICES INC. $5,400.00 08/25/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226129726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,075.00 08/19/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.70 08/19/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137465
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $4,417.96 07/31/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870904
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $459.00 07/31/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870908
Principal investigator 1 SANOFI US SERVICES INC. $4,802.40 07/28/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226129710
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $726.35 06/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870872
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $35,330.00 06/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870876
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $3,750.00 06/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870881
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $1,377.00 06/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870886
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $10,213.85 06/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870888
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $1,780.75 06/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870892
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $1,500.00 06/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870896
Principal investigator 1 ARS Pharmaceuticals Operations, Inc. $675.00 06/30/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
NEFFY OR IM ADRENALIN IN PATIENTS WITH FOOD ALLERGIES AFTER ORAL FOOD CHALLENGE OR IMMUNOTHERAPY No dispute reported 06/30/2026 1245870900
Principal investigator 1 SANOFI US SERVICES INC. $9,738.00 06/16/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226129702
Recipient Regeneron Pharmaceuticals, Inc. $574.00 06/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $675.00 05/28/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184137453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 05/28/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184137455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,350.00 05/28/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184137457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.50 05/28/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184137459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 05/28/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184137461
Principal investigator 1 SANOFI US SERVICES INC. $30,836.25 05/12/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226129693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,300.00 05/08/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS No dispute reported 06/30/2026 1184137447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,812.50 05/08/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS No dispute reported 06/30/2026 1184137449
Recipient Regeneron Pharmaceuticals, Inc. $322.61 05/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122964
Recipient Regeneron Pharmaceuticals, Inc. $689.58 05/01/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS No dispute reported 06/30/2026 1184122966
Recipient Regeneron Pharmaceuticals, Inc. $261.43 04/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122960
Recipient Regeneron Pharmaceuticals, Inc. $264.88 04/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,675.00 03/19/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184137433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $675.00 03/13/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,694.40 03/05/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184137423
Recipient Regeneron Pharmaceuticals, Inc. $246.65 03/01/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 1184122958
Recipient PFIZER INC. $940.00 02/27/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228719387
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,491.35 02/12/2025 Covered Recipient Teaching Hospital
The Childrens Hospital Of Philadelp
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) No dispute reported 06/30/2026 1185549923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $585.00 02/05/2025 Covered Recipient Teaching Hospital
THE CHILDRENS HOSPITAL OF PHILADELP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS No dispute reported 06/30/2026 1184137419
Recipient Regeneron Pharmaceuticals, Inc. $275.00 02/01/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS No dispute reported 06/30/2026 1184122954
Recipient Regeneron Pharmaceuticals, Inc. $255.75 02/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122956